Jim Cramer on Pfizer Inc. (PFE): 'Still, Anything Good There, It Could Fly'
Monday, Nov 18, 2024 6:00 pm ET
3min read Pfizer Inc. (PFE) has been under the spotlight recently, with Jim Cramer, host of CNBC's Mad Money, sharing his thoughts on the company's prospects. In a recent interview, Cramer discussed Pfizer's acquisition of Seagen, the company's oncology pipeline, and its potential for growth. This article explores Cramer's insights and evaluates Pfizer's investment potential based on the available data.
Cramer praised Pfizer's acquisition of Seagen, stating that the deal "strengthens [Pfizer's] pipeline in antibody-drug conjugates (ADCs)." Seagen's expertise in ADCs complements Pfizer's existing oncology portfolio, which includes the successful Prevnar family of vaccines and the recently approved Besponsa for acute lymphoblastic leukemia. The acquisition bolsters Pfizer's pipeline with Seagen's pipeline of ADCs, including ladiratuzumab vedotin (SVB-001) for lung cancer and gilteritinib for acute myeloid leukemia. Cramer believes that Pfizer's oncology division could see significant growth, with the potential for additional approvals and revenue streams.
Pfizer's oncology division has indeed shown promising growth. In the second quarter of 2024, Pfizer's oncology revenue jumped 27% year-over-year, highlighting solid execution in this growth area. The acquisition of Seagen, coupled with Pfizer's own ADC developments, positions the company well for future growth in the oncology market.
However, Pfizer's stock performance has been mixed in recent months. In 2023, the company's revenue decreased by 41.7% compared to the previous year, and earnings fell by 93.25%. Despite these setbacks, analysts remain bullish on the stock, with an average target price of $33.17, representing a 33.43% increase from the latest price.
Cramer acknowledges the challenges Pfizer faces, stating that "anything good there, it could fly." He believes that the company's potential in the oncology sector, driven by the Seagen acquisition and its ADC pipeline, could offset any headwinds the company may face.
In conclusion, Jim Cramer's insights on Pfizer Inc. (PFE) highlight the company's potential in the oncology sector, driven by its acquisition of Seagen and its promising ADC pipeline. While the company's recent financial performance has been mixed, analysts remain bullish on the stock. Investors should carefully evaluate Pfizer's growth prospects, considering both the opportunities and challenges the company faces.
Cramer praised Pfizer's acquisition of Seagen, stating that the deal "strengthens [Pfizer's] pipeline in antibody-drug conjugates (ADCs)." Seagen's expertise in ADCs complements Pfizer's existing oncology portfolio, which includes the successful Prevnar family of vaccines and the recently approved Besponsa for acute lymphoblastic leukemia. The acquisition bolsters Pfizer's pipeline with Seagen's pipeline of ADCs, including ladiratuzumab vedotin (SVB-001) for lung cancer and gilteritinib for acute myeloid leukemia. Cramer believes that Pfizer's oncology division could see significant growth, with the potential for additional approvals and revenue streams.
PFE Total Revenue YoY, Total Revenue
Pfizer's oncology division has indeed shown promising growth. In the second quarter of 2024, Pfizer's oncology revenue jumped 27% year-over-year, highlighting solid execution in this growth area. The acquisition of Seagen, coupled with Pfizer's own ADC developments, positions the company well for future growth in the oncology market.
However, Pfizer's stock performance has been mixed in recent months. In 2023, the company's revenue decreased by 41.7% compared to the previous year, and earnings fell by 93.25%. Despite these setbacks, analysts remain bullish on the stock, with an average target price of $33.17, representing a 33.43% increase from the latest price.
Cramer acknowledges the challenges Pfizer faces, stating that "anything good there, it could fly." He believes that the company's potential in the oncology sector, driven by the Seagen acquisition and its ADC pipeline, could offset any headwinds the company may face.
In conclusion, Jim Cramer's insights on Pfizer Inc. (PFE) highlight the company's potential in the oncology sector, driven by its acquisition of Seagen and its promising ADC pipeline. While the company's recent financial performance has been mixed, analysts remain bullish on the stock. Investors should carefully evaluate Pfizer's growth prospects, considering both the opportunities and challenges the company faces.
